G. Oskay-Oezcelik

发表

Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

Marcus Schmidt, J. Sehouli, P. Harter, 2018, The Lancet. Oncology.

Development of the Berlin Symptom Checklist Ovary (BSCL-O) for the measurement of quality of life of patients with primary and recurrent ovarian cancer: results of a phase I and II study

W. Lichtenegger, J. Sehouli, D. Stengel, 2010, Supportive Care in Cancer.

Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.

U. Neumann, W. Lichtenegger, J. Sehouli, 2008, Anticancer research.

Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.

H. Sommer, W. Lichtenegger, J. Sehouli, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumor- and stromal cell-specific expression of topoisomerase IIα and HER-2/neu in primary and recurrent ovarian cancer: Results of a prospective study.

E. Dahl, A. Rosenthal, I. Klaman, 2009, Molecular medicine reports.

Health-related quality of life during sequential chemotherapy with carboplatin followed by weekly paclitaxel in advanced ovarian cancer: a multicenter phase ii study of the North Eastern German Society of Gynecological Oncology.

H. Sommer, J. Sehouli, J. Einenkel, 2012, Anticancer research.

Clinical management of borderline tumours of the ovary - experience from the "Berlin online tumour conference for gynaecological malignancies".

S. Darb-Esfahani, W. Lichtenegger, J. Sehouli, 2010, Anticancer research.

Clinical management of borderline tumours of the ovary: results of a multicentre survey of 323 clinics in Germany

W. Kuehn, W. Lichtenegger, J. Sehouli, 2009, British Journal of Cancer.

Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone

S. Parsons, S. Al-Batran, P. Wimberger, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Extraperitoneal response to intraperitoneal immunotherapy with catumaxomab in a patient with cutaneous lymphangiosis carcinomatosa from ovarian cancer: a case report and review of the literature

J. Sehouli, H. Woopen, G. Oskay-Oezcelik, 2012, Medical Oncology.

A phase-I trial of pemetrexed plus carboplatin in recurrent ovarian cancer

T. Bauknecht, I. Runnebaum, W. Lichtenegger, 2010, Cancer Chemotherapy and Pharmacology.

Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.

M. Stauch, H. Sommer, W. Lichtenegger, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

956PInfluence of comorbidities on clinical outcome in patients (pts) receiving chemotherapy (CT) + bevacizumab (BEV) for primary advanced ovarian cancer (OC)

J. Sehouli, P. Wimberger, A. Mustea, 2017 .

Brain metastases from epithelial ovarian cancer: overview and optimal management.

Jalid Sehouli, D. Boehmer, W. Lichtenegger, 2009, Anticancer research.

Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone.

S. Parsons, S. Al-Batran, P. Wimberger, 2012 .

What do patients think about CA-125 monitoring in the follow-up? Results from a multicenter trial in 1,060 patients with ovarian cancer.

P. Fasching, K. Münstedt, W. Lichtenegger, 2009, Journal of Clinical Oncology.

Topotecan weekly versus routine 5-day schedule in patients with platinum-resistant ovarian cancer (TOWER): A randomized, multicenter trial of the North-Eastern German Society of Gynecological Oncology (NOGGO).

W. Lichtenegger, J. Sehouli, P. Harter, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study

H. Sommer, W. Lichtenegger, J. Sehouli, 2008, Cancer Chemotherapy and Pharmacology.